Themis Medicare Share Price

<h3><span style="font-size:16px;"><strong>Pharmaceuticals company Themis Medicare announced Q1FY27 results</strong></span></h3> <p _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Consolidated Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c183360516="">Revenue from Operations: The consolidated revenue for Q1FY27 stood at Rs 8,695.69 lakh, representing a growth of 13.62% from Rs 7,653.05 lakh in Q4FY26 (QoQ) and a decline of 10.88% from Rs 9,757.77 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Total Income: The company reported a total income of Rs 8,795.06 lakh in Q1FY27, showing a 9.67% increase compared to Rs 8,019.75 lakh in Q4FY26 (QoQ). On a YoY basis, total income decreased by 10.94% from Rs 9,875.36 lakh in Q1FY26.</li> <li _ngcontent-ng-c183360516="">Net Profit for the Period: The company recorded a net profit of Rs 2,461.14 lakh in Q1FY27, reflecting a growth of 176.99% from Rs 888.54 lakh in Q4FY26 (QoQ). This performance marks a significant turnaround compared to a net loss of Rs 1,421.97 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Total Comprehensive Income: Total comprehensive income for Q1FY27 was Rs 2,442.79 lakh, compared to Rs 882.51 lakh in Q4FY26 (QoQ) and a comprehensive loss of Rs 1,424.77 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Earnings Per Share (EPS): The basic and diluted EPS for Q1FY27 was Rs 2.67, up from Rs 0.96 in Q4FY26 and an improvement from a negative Rs (1.54) in Q1FY26.</li> <li _ngcontent-ng-c183360516="">Exceptional Item: During Q1FY27, the company recorded an exceptional profit of Rs 9,295.34 lakh on the sale of shares.</li> </ul> <p _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Standalone Financial Highlights:</strong></p> <ul> <li _ngcontent-ng-c183360516="">Revenue from Operations: Standalone revenue for Q1FY27 was Rs 8,695.69 lakh, increasing by 13.62% from Rs 7,653.05 lakh in Q4FY26 (QoQ) but decreasing by 10.88% from Rs 9,757.77 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Total Income: Standalone total income for Q1FY27 stood at Rs 8,795.06 lakh, a 9.67% growth over Rs 8,019.75 lakh in Q4FY26 (QoQ) and a 10.94% decline from Rs 9,875.36 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Net Profit for the Period: The standalone net profit for Q1FY27 reached Rs 2,873.72 lakh, showing a substantial increase of 1,362.01% compared to Rs 196.56 lakh in Q4FY26 (QoQ). The company had reported a net loss of Rs 1,537.37 lakh in Q1FY26 (YoY).</li> <li _ngcontent-ng-c183360516="">Profit Before Tax: Profit before tax for Q1FY27 was Rs 4,272.33 lakh, significantly higher than Rs 213.58 lakh in Q4FY26 (QoQ). The profit was bolstered by an exceptional item of Rs 9,966.79 lakh.</li> <li _ngcontent-ng-c183360516="">Earnings Per Share (EPS): Basic and diluted EPS for the standalone entity was Rs 3.12 in Q1FY27, compared to Rs 0.21 in Q4FY26 and Rs (1.67) in Q1FY26.</li> </ul> <p _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Business Highlights:</strong></p> <ul> <li _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Sale of Investment:</strong> During Q1FY27, the company sold 24,97,190 equity shares of its investment in Gujarat Themis Biosyn Limited, an Associate Company, for a total consideration of Rs 100 crore.</li> <li _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Exceptional Gains:</strong> The profit on the sale of the aforementioned investment amounted to Rs 99.67 crore on a standalone basis and Rs 92.95 crore on a consolidated basis.</li> <li _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Subsidiary Dissolution:</strong> The company’s wholly owned subsidiary, Carpo Medicals Limited (UK), was dissolved effective from April 14, 2025. The company has provided for the investment of Rs 0.76 lakh and receivables/advances of Rs 128.63 lakh related to this subsidiary as an exceptional item in the financial statements.</li> <li _ngcontent-ng-c183360516=""><strong _ngcontent-ng-c183360516="">Corporate Changes:</strong> The Board approved the appointment of Mr. Suresh Savaliya as the Company Secretary, Compliance Officer, and Key Managerial Personnel (KMP) effective August 13, 2026, following the resignation of Mr. Nagraj Mogaveera.</li> </ul> <p><a class="lb" href="/get-document/post/pdf/5787039/" target="_blank">Result PDF</a></p>

• Trendlyne
• 1 week 3 days ago

Please refer to our Intimation of change/updation in Email ID of Company Secretary and RTA.

• BSE India
• 2 weeks 4 days ago

Newspaper Publication of Un-audited Financial Results for the quarter ended 30th June, 2026

• BSE India
• 3 weeks ago